secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001104659-26-052081
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck reports Q1 GAAP loss per share of $1.72 on $16.3B sales; narrows and raises full-year guidance
--------------------------------------------------------------------------------

- GAAP EPS loss of $1.72; Non-GAAP EPS loss of $1.28, both include $3.62/share charge for Cidara acquisition.
- Total sales $16.3B, +5% YoY; KEYTRUDA sales $8.0B (+12%), WINREVAIR $525M (+88%).
- Full-year 2026 sales guidance raised to $65.8B-$67.0B; Non-GAAP EPS guidance raised to $5.04-$5.16.
- Announced agreement to acquire Terns Pharmaceuticals; one-time charge ~$5.8B (~$2.35/share) not in guidance.
- Animal Health sales $1.8B (+13%); multiple regulatory approvals including IDVYNSO for HIV.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/0001104659-26-052081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-052081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer